As Restore® opens this new chapter, our Board and I are confident that Steven is the right person to lead the company forward," said Jan Bouten, Chairman of the Restore Board of Directors.
Memphis, TENN. (PRWEB) March 03, 2015
Restore Medical Solutions Board of Directors has appointed Steven M. King as the company’s President and CEO.
Prior to taking the role of President and CEO, Mr. King served as strategy consultant with Restore®. A 30+ year veteran of the healthcare industry, King’s background encompasses sales, marketing, operations and advisory boards, as well as raising capital from the private markets. Most recently, Mr. King served as Entrepreneur in Residence (EIR) for the CONNECT Springboard Program in San Diego and as mentor for the Memphis Bioworks “ZeroTo510” Accelerator Program.
Earlier in his career Mr. King served as Executive Vice President of Sales and Marketing for InSight Health Corporation, Executive Vice President of Sales for Woodside Biomedical (acquired by Abbott Laboratories) and Area Vice President for Cardinal Health. In addition, Mr. King was Area Vice President for Pyxis Corporation, where he played an instrumental role in positioning the company for its initial public offering and it subsequent sale to Cardinal Health for approximately $1 billion. In 1995, Pyxis Corporation was ranked number one on the "Inc. Magazine" list of the 100 fastest growing public companies. Earlier in his career, Mr. King worked in sales management with Eli Lilly & Company.
"As Restore® opens this new chapter, our Board and I are confident that Steven is the right person to lead the company forward," said Jan Bouten, Chairman of the Restore Board of Directors. "He has a proven ability to create strategic clarity, drive innovation and growth, ensure disciplined execution, and deliver results. We believe that his passion for healthcare technology will help ensure that Restore® continues to deliver cost-effective innovations that improve the quality of care."
Ryan Ramkhelawan, who has been serving as CEO, will transition to the role of Chief Technology Officer and will focus exclusively on innovation and product development. Shawn Flynn, who has been serving as President, will transition to Senior Vice President of Customer Operations and will spearhead the clinical adoption and customer experience efforts.
“We are extremely pleased that Steven is joining the company. His extensive experience in the medical device industry and as an entrepreneur is the perfect fit for our growth objectives,” said Gary Stevenson, Managing Partner at MB Venture Partners and Restore Board Member.
"I am honored to have been asked to take this role during a time of unprecedented opportunity for the company,” King said. “Restore®, with its deep experience in the perioperative and sterile processing arena, is well-positioned to have a substantial impact in healthcare by improving patient safety and quality of care. I look forward to working closely with Restore’s Board of Directors and with the company’s co-founders to achieve the goal of establishing Restore® as the standard bearer for the care, maintenance and cleaning of surgical instruments.
About Restore Medical Solutions
Founded in 2012, Restore Medical Solutions, Inc. headquartered in Memphis, Tenn., is a privately-held medical device company specializing in the development, manufacturing and marketing of innovative technology to address the challenges associated with the care, maintenance and cleaning of surgical instruments. Restore Medical Solutions, Inc. is ISO 13485 certified w/CAMDACAS designation.
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early- stage investor. Its mission is to enable and create high-growth, Tennessee-based companies and jobs in the healthcare and technology fields by providing seed capital and experienced hands-on mentorship and leadership.
About MB Venture Partners
MB Venture Partners is a Memphis-based venture capital firm that provides capital and strategic direction to life sciences start-ups. The firm invests in medical device and biotechnology companies at all stages. Since inception in 2001, the firm has invested in 40 start- ups.